Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced seven

Premier, Inc. to Report Fiscal 2023 First-Quarter Results and Host Conference Call on November 1, 2022: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. to Report Fiscal 2023 First-Quarter Results and Host Conference Call on November 1, 2022


Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2023 first quarter on Tuesday, November 1, 2022, at approximately 6:30 a.m. ET. The company will

Novocure to Report Third Quarter 2022 Financial Results: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure to Report Third Quarter 2022 Financial Results


Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2022 on Thursday, October 27, 2022, before the U.S. financial markets open. Novocure management

Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business


Novocure (NASDAQ: NVCR) today announced the creation of its U.S. CNS (central nervous system) Cancers Franchise. This new organization will add resources, streamline decision-making and improve

Thomas Jefferson University and Acadia Healthcare Establish Primary Affiliation Agreement: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Thomas Jefferson University and Acadia Healthcare Establish Primary Affiliation Agreement


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) and Thomas Jefferson University today announced that Acadia’s Belmont Behavioral Health Hospital has entered into a formal affiliation agreement with

Select Acadia Healthcare Hospitals to Participate in Clinical Trial for Acute Suicidal Ideation and Behavior in Major Depression Drug: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Select Acadia Healthcare Hospitals to Participate in Clinical Trial for Acute Suicidal Ideation and Behavior in Major Depression Drug


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that select facilities from its network of acute care behavioral health hospitals will participate in a registration directed trial to

Xencor Appoints Nancy Valente, M.D., to Board of Directors: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Appoints Nancy Valente, M.D., to Board of Directors


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the

Charles River Laboratories to Present at Baird and Morgan Stanley Conferences: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences


Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences in New York, including:




  • Baird 2022 Global Healthcare

Premier, Inc.’s Subsidiary Contigo Health, LLC, to Acquire Contracts With 900,000 Providers and Licenses to Cost Containment Technology: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc.’s Subsidiary Contigo Health, LLC, to Acquire Contracts With 900,000 Providers and Licenses to Cost Containment Technology


Premier, Inc. (NASDAQ: PINC) subsidiary Contigo Health, LLC, a provider of comprehensive services that optimize employee health benefits, today announced an agreement to acquire key assets from

Charles River and Cure AP-4 Announce Gene Therapy Manufacturing Collaboration: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River and Cure AP-4 Announce Gene Therapy Manufacturing Collaboration


Charles River Laboratories International, Inc. (NYSE: CRL) and Cure AP-4, a non-profit foundation dedicated to raising funds and awareness about Adapter-Protein 4 Hereditary Spastic Paraplegia

Novocure to Participate in Upcoming Investor Conferences: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure to Participate in Upcoming Investor Conferences


Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Executive Chairman, and Ashley Cordova, Chief Financial Officer, will

Charles River Laboratories Expands Contract Vivarium Space on West Coast: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Expands Contract Vivarium Space on West Coast


Charles River Laboratories International, Inc. (NYSE: CRL) today announced the addition of five Charles River Accelerator and Development Lab (CRADL™) locations in California and Washington. CRADL

Premier, Inc. Reports Fiscal-Year 2022 Fourth-Quarter and Full-Year Results: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Reports Fiscal-Year 2022 Fourth-Quarter and Full-Year Results


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal-year 2022 fourth quarter and full year ended June 30, 2022

Novocure Hosts U.S. Sen. Maggie Hassan at Company’s Portsmouth Facility: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Hosts U.S. Sen. Maggie Hassan at Company’s Portsmouth Facility


On Tuesday, Aug. 9, U.S. Sen. Maggie Hassan (NH) joined members of Novocure’s leadership team to tour the company’s U.S. headquarters in Portsmouth, New Hampshire, and learn more about Novocure’s

Charles River Laboratories is First CDMO in North America to Receive EMA Approval to Commercially Produce an Allogeneic Cell Therapy Drug Product: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories is First CDMO in North America to Receive EMA Approval to Commercially Produce an Allogeneic Cell Therapy Drug Product


Charles River Laboratories, International Inc. (NYSE: CRL) announced it has received regulatory approval, in the form of Good Manufacturing Practice (GMP) certification, to commercially produce

Chemed Corporation Declares Quarterly Dividend of 38 Cents:
Chemed Corporation Declares Quarterly Dividend of 38 Cents


Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 38-cents per share on the Company’s capital stock, payable on September 2, 2022

Premier, Inc. Declares an Increase to Quarterly Cash Dividend: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Declares an Increase to Quarterly Cash Dividend


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors approved a 5% increase to the company’s quarterly cash dividend

Xencor Reports Second Quarter 2022 Financial Results: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Reports Second Quarter 2022 Financial Results


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial

Charles River Laboratories Announces Second-Quarter 2022 Results: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Announces Second-Quarter 2022 Results


Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2022. For the quarter, revenue was $973.1 million, an increase of 6.4% from $914.6

Novocure Reports Second Quarter 2022 Financial Results: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Reports Second Quarter 2022 Financial Results


Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive forms

Chemed Reports Second-Quarter 2022 Results:
Chemed Reports Second-Quarter 2022 Results


Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest

Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will

Acadia Healthcare Reports Second Quarter 2022 Results and Raises 2022 Guidance: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Reports Second Quarter 2022 Results and Raises 2022 Guidance


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the second quarter ended June 30, 2022.



Second Quarter Highlights




  • Revenue totaled $651.7 million, an

Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program


Novocure today announced the recipients of the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The AACR-Novocure Grants for Tumor Treating Fields Research Program

Acadia Healthcare Forms Joint Venture With ECU Health to Build a Modern Behavioral Health Hospital in Eastern North Carolina: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Forms Joint Venture With ECU Health to Build a Modern Behavioral Health Hospital in Eastern North Carolina


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with ECU Health (formerly Vidant Health), eastern North Carolina’s premier health system. The new